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Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children. Aberrant Hedgehog (Hh) signaling is charac-
teristic of the embryonal subtype (ERMS) and of fusion-negative alveolar RMS. In the mouse, ERMS-like tumors can be induced
by mutations in the Hh receptor Patched1 (Ptch). As in humans these tumors show increased Hh pathway activity. Here we
demonstrate that the treatment with the active form of vitamin D3, calcitriol, inhibits Hh signaling and proliferation of murine
ERMS in vivo and in vitro. Concomitantly, calcitriol activates vitamin D receptor (Vdr) signaling and induces tumor diﬀer-
entiation. In addition, calcitriol inhibits ERMS growth in Ptch-mutant mice, which is, however, a rather late response. Taken
together, our results suggest that exogenous supply of calcitriol could be beneﬁcial in the treatment of RMS, especially in those
which are associated with aberrant Hh signaling activity.
1.Introduction
The Hh signaling pathway is involved in the regulation of
proliferation and diﬀerentiation of diﬀerent cell types, tis-
sues, and organs [1]. In the absence of Hh, Ptch suppresses
the activity of its signaling partner Smoothened (Smo). Hh
pathway activation is initiated when Hh ligands bind to
Ptch, thereby relieving its inhibition on Smo. This results
in the transcription of Hh target genes including Gli1 [1].
Aberrant Hh signaling caused by inactivating Ptch muta-
tions, activating Smo mutations, or Hh overexpression leads
to tumor formation [2].
RMS is a myogenic tumor and the most common soft
tissue sarcoma in children. RMS occurs as 2 major subtypes,
whichareERMSandalveolarRMS(ARMS).ARMSoccursin
adolescents and young adults. Seventy-ﬁve percent of ARMS
are characterized by chromosomal translocations resulting
in fusion genes consisting of the DNA-binding domain of
the PAX7 or PAX3 and the transactivation domain of the
forkhead transcription factor FOXO1 [3]. Approximately
25% of ARMS lack this translocation and are thus fusion
negative, despite classical alveolar histology [4, 5]. ERMS is
the more frequent RMS subtype and accounts for two-thirds
of all RMS. It predominantly occurs in infants and young
children [3, 6].
Therapies of RMS are typically multidisciplinary and
combine complete surgical excision or local irradiation with
chemotherapy. The 5-year overall survival for RMS is appro-
ximately 73% for ERMS and 48% for ARMS [7]. However,
the survival rate for metastatic disease is only 10–30% for
ARMS [8] and approximately 40% for ERMS [9]. This shows
the need for new treatment options especially for patients
with recurrent or metastatic RMS.2 Sarcoma
We and others recently showed that sporadic ERMS and
fusion-negative ARMS overexpress Hh target genes [10, 11].
This ﬁnding has important implications for molecular tar-
geted therapies in these subtypes, because they may be sen-
sitive to a treatment with Hh pathway inhibitors.
Mice heterozygous for the Hh receptor Ptch develop
embryonal subtype-like RMS [12–14]. Therefore, these mice
present a suitable model for the preclinical evaluation of Hh
pathway antagonists in the treatment of ERMS, in which Hh
signaling is active. We recently showed that the speciﬁc Smo-
inhibitor cyclopamine does not exert any antitumor eﬀect
in this mouse model, although it partially suppressed Hh
pathway activity [15]. This implies that Smo-independent
events may contribute to progression of Hh-associated RMS.
Thus, therapy of Hh-associated RMS may require targeting
of additional signaling pathways.
Vitamin D3 and its derivatives are known to have anti-
proliferative eﬀects on diﬀerent cancers and cancer cell lines
including the RMS cell line HS729 [16, 17]. Until recently,
the antitumoral eﬀects of vitamin D3 were solely explain-
ed by binding of the biologically active form of vitamin D3,
calcitriol (1α,25(OH)2D3), to the Vdr and the subsequent
regulation of Vdr-bound genes. This so-called “genomic”
calcitriol/Vdr-signaling can be monitored by the transcrip-
tion of Cyp24a1. In addition, calcitriol elicits rapid, so-called
“nongenomic” (i.e., transcription-independent) eﬀects such
as calcium inﬂux.
Importantly, we recently demonstrated that calcitriol
inhibits growth of basal cell carcinoma (BCC), which is an
Hh/Ptch-driven tumor [18]. In BCC, the antitumoral pro-
perty of calcitriol is accompanied by activation of the Vdr
signaling pathway, by induction of diﬀerentiation and by
simultaneous inhibition of Hh signaling activity [18]. The
latter eﬀect is in line with data published by Bijlsma et al.
who provided ﬁrst evidence that vitamin D3 inhibits the Hh
pathway at the level of Smo [19].
The crosstalk between calcitriol/Vdr and Hh pathways
prompted us to investigate the eﬀect of calcitriol on Vdr
and Hh signaling, growth, apoptosis, and diﬀerentiation of
Hh-associated RMS in vitro and in vivo using the Ptchneo67/+
m o u s em o d e lf o rE R M S[ 12].
2.MaterialandMethods
2.1. Compounds. Calcitriol (Sigma-Aldrich, Germany) and
cyclopamine (Toronto Research Chemicals Inc., Canada)
weredissolvedinethanol(EtOH).Finalconcentrationsforin
vitroexperiments are indicated in the respective experiments
and correspond to those normally used in culture [16, 20,
21]. For in vivo use, calcitriol was diluted individually for
each animal in 20μL EtOH/1200μL sterile sunﬂower oil
(Sigma-Aldrich) to obtain a ﬁnal concentration of 50ng/kg
in 50μL.
2.2.AnimalsandTreatmentofTumor-BearingPtchneo67/+ Mice
with Calcitriol. Heterozygous Ptchneo67/+ mice were main-
t a i n e do nam i x e dC 5 7 B L / 6× Balb/c background, which
rendersthemsusceptibleforERMS-liketumors[12,22].The
tumors are deﬁcient in Ptch and show a strong Hh signaling
activity [23, 24].
ERMS-bearing Ptchneo67/+ mice were subjected to VCT
(volumen computer tomography) analysis (see below). Ani-
mals with similar tumor volumes were selected and rando-
mized into two groups. After randomization, mice were
injected daily i.p. with either 50ng/kg/d calcitriol or vehicle
for8weeks.50%oftheanimalsofeachgroupwererandomly
euthanizeddirectlyaftertreatment.Theremainingmicewere
observed for additional 4 weeks. Tumors were dissected 24h
after the last calcitriol injection or after the medication-free
period and were used for molecular analyses.
Mice were fed with calcium- and phosphate-reduced and
vitamin D3-free food (ssniﬀ Spezialdiaeten, Soest, Germany;
E15312-14) [25] one week before and during the injection
period and for one week thereafter.
All animals were treated and housed in accordance with
the German animal protection law.
2.3. Measurement of Tumor Size. Imaging of tumors was
performed using a laboratory animal ﬂat panel volume com-
puter tomography (GE Global Research; USA) as described
[15, 26].
2.4. Analysis of Calcium Blood Serum Values. 100μL of blood
were collected from the retroorbital plexus. Serum calcium
concentrations were measured using an O-cresolphthalein-
based assay (cobas, Roche Diagnostics GmbH, Germany).
2.5. Histopathology and Immunohistochemistry. ERMS and
normal skeletal muscle (SM) of Ptchneo67/+ mice were em-
bedded in paraﬃn for histological analyses or were used
for isolation of total RNA (see below). The identity of
ERMS was conﬁrmed by examination of H- & E-stained sec-
tions. Paraﬃn sections were stained using an anti-Ki67 and
antiactive caspase 3 antibody as described [15].
2.6.CellLinesandPrimaryCellCultureofRMS. Primary cul-
turesderivedfromERMSofPtchneo67/+ micewereestablished
as published previously [15].
2.7. Cell Culture Experiments. For gene expression analysis
andBrdUincorporationorCaspase3and7(eﬀectorcaspases
involved in apoptosis) assays, 100,000 and 4,000 cells/well
were seeded in 6-well and 96-well plates, respectively. After
24h, the cells were washed and incubated for additional
48h with medium supplemented with 10nM calcitriol, 5μM
cyclopamine, or ethanol.
Cell proliferation was measured after BrdU-pulsing for
the last 22h using a cell proliferation BrdU ELISA (Roche
Diagnostics GmbH).
Activity of Caspase 3 and 7 was measured using the
Caspase-Glo 3/7 Assay (Promega) according the manufac-
turer’s instructions.
Data shown are representative for at least three indepen-
dent experiments each performed in triplicate.
2.8. Reverse Transcription and Quantitative RT-PCR Analyses.
Total RNA was extracted using TriReagent (Sigma-Aldrich).Sarcoma 3
Synthesis of cDNA and primer combinations for ampliﬁ-
cation of 18S rRNA, Cyp24a1, Vdr, Gli1, MyoD1, p27,a n d
MRF4 transcripts used for quantitative real-time PCR (qRT-
PCR) were described previously [15, 18, 27]. Ampliﬁcation
of 18S rRNA was performed as an endogenous control for
the normalization of target gene expression. The amount of
target and endogenous reference was determined using the
relative standard curve method. Each sample was measured
in triplicates.
2.9. Statistics. Mann-Whitney-U testing was performed to
determine the signiﬁcance of the results from qRT-PCR-
analyses, BrdU incorporation assays, caspase 3/7 activity
assays, Ki67 counts, and calcium serum concentrations.
ANOVA models were ﬁtted to test for diﬀerences in the
tumor volumes (logarithmic transformed) between treat-
mentatbaselineandduringfollow-upgroups.Tukey’smeth-
od was used to adjust for multiple testing. The global level of
signiﬁcance was set to 5.
3. Results andDiscussion
ERMS of Ptch-mutant mice showed high levels of Vdr tran-
scription (Figure 1(a)). This is similar to human RMS cell
lines, which highly express VDR [17]. Short-term cultures of
murine ERMS revealed that treatment with 10nM calcitriol
increased the expression of the Vdr target gene Cyp24a1,
whereas it downregulated the expression of the Hh target
gene Gli1 (Figure 1(b)). As expected, treatment of the cells
with 5μM of the speciﬁc Hh-antagonist and Smo-inhibitor
cyclopaminedidnotactivateVdrsignaling(Figure 1(b)),but
strongly inhibited Hh signaling activity (Figure 1(b)).
To assess the antiproliferative eﬀect of calcitriol, BrdU-
incorporation assays were conducted. Calcitriol eﬃciently
inhibited the proliferation of ERMS primary cultures, and
its anti-proliferative eﬀect was comparable to that of cyclo-
pamine (Figure 1(c)).
In addition, calcitriol induced a signiﬁcant increase in
the expression of the muscle diﬀerentiation markers MyoD,
MRF4,a n dp27 (Figure 1(d); [28, 29]). The induction of
muscle diﬀerentiation was speciﬁc for calcitriol and was not
seen with cyclopamine.
The before-mentioned eﬀects were not accompanied by
activation of caspase 3/7 activity (Figure 1(e)).
These data show that calcitriol inhibits proliferation of
ERMS cells in vitro. This is similar to cyclopamine, which
likewise blocks proliferation of murine (see Figure 1(c)) and
human ERMS cell lines [30]. In addition, calcitriol induces
MyoD expression. This is speciﬁc for calcitriol, because cy-
clopamine did not change MyoD levels, although Hh sig-
naling has been reported to regulate the expression of this
gene [31]. Similarly calcitriol, but not cyclopamine, induces
expression of MRF4 and p27, both of which drive cell cycle
exitanddiﬀerentiationofmyoblasts[32,33].Sincecalcitriol-
mediated regulation of muscle growth and diﬀerentiation is
either calcium or Vdr related [34–36], the calcitriol-induced
expression of muscle diﬀerentiation markers in ERMS is
likely due to one of these mechanisms.
Together, our in vitro analyses demonstrate that calcitriol
inhibits Hh signaling activity and cell proliferation of Hh-
associated ERMS in a similar manner when compared to
cyclopamine. However, in contrast to cyclopamine, calcitriol
additionally induces Vdr signaling and diﬀerentiation of the
tumors.
Next, we assessed the in vivo eﬀects of calcitriol in the
Ptchneo67/+ mouse model for ERMS. ERMS-bearing mice
were randomly divided into two groups. Tumor volumes
of these animals at the beginning of the study did not sig-
niﬁcantly diﬀer within each group and among groups (tested
by ANOVA). Mice in the treatment group (n = 14) obtained
a daily dose of 50ng/kg calcitriol over a period of 8 weeks,
whereas animals in the control group were treated with
vehicle (n = 10). At the end of the therapy, tumor volume of
all animals was measured by VCT analysis, and 7 calcitriol-
and 4 vehicle-treated mice were sacriﬁced for molecular
tumor analysis. To detect delayed eﬀects of the treatment,
the remaining 7 and 6 animals, respectively, were observed
for 4 additional weeks (observation period in Figure 2(a)),
subjected to VCT and euthanized thereafter.
Calcitriol therapy led to a signiﬁcant and reversible in-
crease in serum calcium concentrations (Figure 2(a)), with-
out causing weight loss, hypercalcemia-driven kidney dam-
age, or signs of nephrocalcinosis (data not shown).
In Figure 2(b) fold increase of tumor volumes of the
calcitriol- or vehicle-treated mice is shown. The volumes of
the majority of RMS increased irrespective of treatment, and
at the end of the 8-week treatment period the average overall
tumor growth rate was not diﬀerent between the cohorts
(Figure 2(b); 8 weeks). In the medication-free observation
time, the tumors of the control group grew steadily and
on average enlarged more than 4-fold over their baseline
size (Figure 2(b); 12 weeks). In contrast, tumors treated
with calcitriol remained stable. The diﬀerence between the
cohorts was however not signiﬁcant.
As already observed in cell culture, the in vivo calcitriol
treatmentresulted in an activation of Vdr signaling. This was
revealed by a signiﬁcant induction of Cyp24a1 transcription
in the tumors (Figure 2(c)). Cyp24a1 induction was seen
directly after the 8-week treatment period and was sustained
in the 4-week medication-free period. The induction of
Cyp24a1 is consistent with the preexisting expression of the
calcitriol receptor Vdr in ERMS (see Figure 1(a)). We also
observed an increase in Vdr expression, which was becoming
signiﬁcant after the medication-free period (Figure 2(c)).
Thus, Vdr induction seems to be a late eﬀect of the calcitriol
treatment. Induction of Vdr expression is in line with the
recentobservationthatactiveVdrsignalingregulatestheVdr
expression in a positive feed-back loop [37]. The increase
in Vdr may also account for its sustained signaling activity
during the medication-free period (see elevated Cyp24a1
expression levels at 12 weeks in Figure 2(c)).
Moreover, the calcitriol treatment resulted in inhibition
of Hh signaling activity as revealed by decreased Gli1 levels
(Figure 2(c)). Although calcitriol-mediated inhibition of
Gli1 expression was observed at the end of therapy, it became
signiﬁcant after the medication-free period (see decreased
Gli1 expression at 12 weeks in Figure 2(c)). Thus, similar4 Sarcoma
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Figure 1: Calcitriol inhibits Hh signaling and proliferation and induces Vdr signaling and diﬀerentiation of primary ERMS cultures of
Ptchneo67/+ mice. (a) Vdr expression levels of ERMS (n = 8) compared to normal skeletal muscle (SM; n = 8). (b) Gli1 and Cyp24a1
expression levels and (c) BrdU incorporation of primary ERMS cultures after treatment with vehicle (EtOH), calcitriol, or cyclopamine
(CP). (d) MyoD1, MRF4,a n dp27 expression levels and (e) activity of caspase 3 and 7 of primary ERMS cultures after treatment with
EtOH, calcitriol or CP. Values of vehicle-treated controls for Gli1, MyoD1, MRF4,a n dp27 expression were set to 1. Expression levels were
normalized to the expression of 18S rRNA gene. For BrdU incorporation or caspase 3/7 assays, cells treated with serum-free medium or
500nM staurosporine (Sigma-Aldrich) served as positive controls, respectively. The values of BrdU incorporation and caspase 3/7 activity
represent the percentage of respective vehicle-treated control, which was set to 1. Asterisks: P<0.05; error bars: mean ± SD.Sarcoma 5
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Figure 2:CalcitriolinhibitsHhsignalingandproliferationandinducesVdrsignalinganddiﬀerentiationofERMSinPtchneo67/+ miceinvivo.
(a) Calcitriol treatment scheme and calcium serum concentrations of ERMS-bearing Ptchneo67/+ mice. Animals were either sacriﬁced directly
at therapy end (8 weeks of treatment) or after an additional 4-week observation period (dashed arrow). (b) Tumor volume was determined
by VCT analysis before therapy (before), at the end of therapy (8 weeks), and 4 weeks thereafter (8 + 4 weeks). Given is the relative median
tumorsize(horizontalbars)foreachtimepoint,theindividualtumorvolumes(dots),andthestandarddeviationoftumorvolumina.ERMS
treated with calcitriol (black) or vehicle (grey). Median tumor volume before onset of treatment was set as 1. Median of the absolute tumor
volumes at time point of randomization was 0.011cm3 ±SEM 0.0033. (c) Gli1, Cyp24a1,a n dVdr,( d )MyoD1, MRF4,a n dp27 expression
levels and (e) percentages of Ki67+ tumor cells/all tumor cells of ERMS after calcitriol-treatment for 8 weeks (8 weeks) or after the additional
4-week observation period (8 + 4 weeks) compared to vehicle-treated tumors (vehicle). Expression levels were normalized to the expression
of 18S rRNA gene. Values of vehicle-treated controls for Gli1, Vdr, MyoD1, MRF4,a n dp27 expression were set to 1. Values of vehicle-treated
controls for Ki67+ tumor cells were set to 100%. Asterisks: P<0.05; error bars: mean ± SD.6 Sarcoma
to Vdr expression, signiﬁcant downregulation of Gli1 rather
seems to be a delayed eﬀect of calcitriol. Late eﬀects also
included the induction of the muscle diﬀerentiation markers
MyoD, MRF4,a n dp27 (Figure 2(d)). Although a trend in
upregulation of these markers was already seen after end of
therapy, it became signiﬁcant after the 4-week observation
period (Figure 2(d)).
Finally, calcitriol signiﬁcantly inhibited the proliferative
capacity of the tumors as revealed by a decrease in Ki67+
cells by 48% and 72% at therapy end and after the additional
observation period, respectively (Figure 2(e)). An increased
activity of the eﬀector caspase 3 was not detected (data not
shown).
At the ﬁrst glance, the signiﬁcant 48% decrease of Ki67+
cells directly at therapy end is in contrast with the sus-
tained ERMS growth as measured by VCT (see “8 weeks”
values in Figures 2(b) and 2(e)). However, it is well known
that computer-assisted tumor size measurements have limi-
tations. For example, this method is inaccurate in diﬀeren-
tiating viable tumor from ﬁbrotic or necrotic tissue.
Consequently, the degree of response may be underesti-
mated. Computer tomography is also limited in measuring
responses in tumors that do not change in size during ther-
apy [38]. This is the case in our present study. Thus, besides
the signiﬁcant decrease of Ki67+ cells, signiﬁcant activation
of Vdr signaling (see “8 weeks” value in Figure 2(c)) indi-
cated a molecular eﬀect of calcitriol, despite lack of tumor
size reduction. In addition, a moderate decrease in Hh sig-
naling activity and an increase in muscle diﬀerentiation were
already detectable at therapy end.
Interestingly, decrease of Hh signaling activity and
increase of muscle diﬀerentiation became signiﬁcant after
the medication-free observation period, when ERMS growth
stagnated and when Ki67+ tumor cells were reduced by 72%
(see “8+4 weeks” values in Figures 2(b) and 2(e)). This sug-
geststhatbothinhibitionoftheHhsignalingcascadeanddif-
ferentiation processes are required for a measurable growth
inhibition of ERMS. Activity of Hh signaling and diﬀeren-
tiation are however unrelated to each other, because appli-
cation of the speciﬁc Hh inhibitor cyclopamine does not
impact ERMS diﬀerentiation (see Figure 1(d) and Ecke et al.
[15]f o rin vitro and in vivo experiments, resp.).
Our data also implicate that most of the calcitriol-
mediated eﬀects (i.e., induction of diﬀerentiation, inhibition
of Hh signalling, and tumor growth) are not immediate but
ratherlatetumorresponses.Thereasonforthisphenomenon
is currently unknown. One explanation could be the fact
that ERMS of Ptchneo67/+ mice are slowly growing tumors.
This may render them fairly resistant to molecular changes
that requir for example, cell cycle progression. Furthermore,
the lack of an immediate tumor growth response suggests
that calcitriol has no acute cytotoxic eﬀects on the tumor
cells. Finally, the relatively poor in vivo eﬀects of calcitriol
in the present study may also be due to underdosing of
calcitriol.Thisassumptionarisesfromourrecentstudyusing
100ng calcitriol/kg daily for 8 weeks in the treatment of
Ptch-associated BCC in mice [18]. As in ERMS, calcitriol
led to a signiﬁcant reduction of Hh signaling activity and
to an induction of Vdr signaling in BCC. Calcitriol also
provoked a signiﬁcant decrease in Ki67+ cells and the
expression of relevant diﬀerentiation markers. Thus, these
molecular changes are general features of calcitriol and not
a characteristic of the respective tumor entity. However, in
contrast to the present study, calcitriol resulted in a strong
and signiﬁcant growth inhibition of BCC [18]. Therefore,
it is certainly important to repeat the ERMS study using
calcitriol at a dose of 100ng/kg/d, which is well tolerated by
mice [18]. An elongation of the treatment period (e.g., 12
or 16 weeks) may be beneﬁcial as well, because most of the
calcitriol-mediated changes seem to be late eﬀects in ERMS.
4. Conclusions
Despite improvements over the last decades in the therapy of
RMS the survival rate for metastatic RMS is still low. Thus
new treatment options especially for patients with recurrent
or metastatic RMS are needed. Our present study demon-
strates that the application of the active form of vitamin
D3, calcitriol, activates Vdr signaling and diﬀerentiation and
additionally inhibits Hh signaling and proliferation of ERMS
tumor cells in vitro and in vivo.T h u sc a l c i t r i o lc o u l db e
beneﬁcial in the treatment of these tumors. Particularly RMS
showing aberrant Hh signaling activity may be responsive to
calcitriol.
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